Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference21 articles.
1. Albert-Vartanian A, Boyd MR, Hall AL, Morgado SJ, Nguyen E, Nguyen VP, et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther. 2016;41:371–82. https://doi.org/10.1111/jcpt.12404.
2. Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382:222–32. https://doi.org/10.1056/NEJMoa1912770.
3. Wooldridge TD, Mccafferty K, Schoemig M, Szabolcs Csiky B, Zwiech R, Wen W, et al. Efficacy and safety of difelikefalin for moderate-to-severe CKD–associated pruritus: a global phase 3 study in hemodialysis patients (KALM-2) [abstract FR-OR24]. J Am Soc Nephrol. 2020;31(suppl):22–3.
4. Korsuva (difelikefalin) [package insert]. Stamford: Cara Therapeutics, Inc.; 2021.
5. Fishbane S, Mathur V, Germain MJ, Shirazian S, Bhaduri S, Munera C, et al. Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients. Kidney Int Rep. 2020;5:600–10. https://doi.org/10.1016/j.ekir.2020.01.006.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献